|
MKRN2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
1.2241999969298E-08 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
3.470000E-01 |
| Stage1-vs-Stage3 |
8.422800E-03 |
| Stage1-vs-Stage4 |
9.59720000026643E-07 |
| Stage2-vs-Stage3 |
1.048060E-02 |
| Stage2-vs-Stage4 |
1.036410E-04 |
| Stage3-vs-Stage4 |
1.030600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
8.07800049074103E-10 |
| Normal-vs-Asian |
1.68443037296129E-12 |
| Caucasian-vs-AfricanAmerican |
8.095200E-01 |
| Caucasian-vs-Asian |
9.956200E-01 |
| AfricanAmerican-vs-Asian |
7.961200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.65023591750469E-14 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
5.698000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62503344114384E-12 |
| Normal-vs-Age(81-100Yrs) |
1.6298499999956E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.142600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.126400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.961400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.137600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.371000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.202200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.68520000000316E-05 |
| Classical-VS-Follicular |
1.437880E-03 |
| Classical-VS-Other |
6.987000E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
1.18209999566687E-08 |
| Tall-VS-Other |
1.034780E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
4.782400E-01 |
| Follicular-VS-Normal |
1.33230000032292E-07 |
| Other-VS-Normal |
8.815200E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.88418203051333E-15 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
1.150640E-04 |
|
|
